Stifel 2026 Healthcare Conference - KESTRA MEDICAL TECHNOLOGIES LTD

Financial Performance:

• Fiscal 2027 Q1 results exceeded expectations, leading to a full-year guidance increase of more than double the initial beat.
• The company operates on a rental model with a target gross margin expansion trajectory: currently in the mid-70% range, aiming for low-90% entitlement as in-network payer coverage expands (currently converting from 67% at IPO to low-80s).
• Long-term gross margin guidance raised to the mid-70s over the next 2-3 years, driven by volume leverage and the shift of patients from out-of-network to in-network reimbursement.
• Path to profitability is expected within the next couple of years, supported by 20% operating expense growth to fuel top-tier market share gains.
• Revenue cycle management is increasingly automated via AI to handle prior authorizations and medical record reviews, reducing reliance on clinical teams for transactional tasks.

Guidance and Future Outlook:

• Market growth for Wearable Cardioverter Defibrillators (WCDs) accelerated to 14% year-over-year, a rate management deems durable due to a large addressable market of 850,000 indicated patients with only 1-in-7 currently prescribed the device.
• Management expects a long-term growth story driven by the expansion of clinical indications, particularly for non-ischemic cardiomyopathy (heart failure) patients, who were previously under-served.
• Full-year FY27 performance is supported by the productivity ramp of ~50 new sales territories added in FY26, with an additional 30-40 territories planned for the current year.
• Profitability milestones are tied to achieving top-tier growth supported by AI-enabled operational efficiency and expanding in-network payer contracts across the US (3,000+ payers).

Business Segments and Product Lines:

• Core business remains the Assure platform (WCD), which is being evolved into an extensible monitoring platform capable of delivering therapeutic and diagnostic capabilities similar to emergency room monitors but in a wearable format.
• Blood Pressure Monitoring: A co-development project with BioBeat is in R&D; regulatory clearance is anticipated in the short term, serving as a differentiator and potential standalone revenue generator.
• Late-Stage Innovation: A new capability to extend issuer performance (beyond VT/VF therapy) is nearing milestone completion, with FDA submission targeted before the end of the calendar year.
• Service Model Expansion: Creation of a Senior VP of Customer Experience role to scale support infrastructure, ensuring prescriptions are fulfilled within 24-48 hours and enhancing the patient/physician interface.

Market and Competitive Landscape:

• The WCD market is transitioning from a monopoly to a duopoly; Kestra's entry has helped double the market growth rate as the category gains broader clinical acceptance.
• Over 40,000 patient clinical data points (21,000 from Kestra's ACE-PASS study + 19,000 from competitor) now validate higher risks in non-ischemic cardiomyopathy patients, driving broader adoption.
• Key payer expansion: A previously non-coverage national payer for non-ischemic patients has recently updated its policy to cover this segment based on new data, signaling a shift in reimbursement trends.
• Independent medical bodies, such as the Heart Rhythm Society (HRS), have published guidelines supporting appropriate WCD use, further legitimizing the category.

Risks and Challenges:

• Scaling the business while maintaining service excellence (24-48 hour fulfillment) and matching supply/demand for inventory remains a primary operational challenge.
• Payer landscape complexity: Navigating a "long tail" of over 3,000 US payers to achieve in-network entitlement requires sustained effort and time.
• Guideline adoption timing: While clinical evidence supports expanded use, the specific timing for formal guideline upgrades remains unpredictable as the industry works to secure long-term survival data (post-discharge through 6 months).

Management Commentary and Tone:

• Management tone is highly confident, emphasizing successful execution, "best-in-class" service, and a clear line of sight to profitability.
• CEO Brian Webster stated his focus is shifting from quarterly execution to long-term strategy (4-5 years) due to high confidence in the operational team.
• CFO Basim Maboub highlighted the predictability of the business model, citing consistent run rates and the proven productivity curve of new sales representatives.
• The leadership team emphasizes competing on all fronts: product, service, sales, and finance, with AI serving as a key lever for margin expansion and operational leverage.

Analyst Questions and Answers:

• Market Dynamics: Analysts asked about the sustainability of the 14% market growth; Management attributed this to a "wake-up call" effect where competition amplifies category awareness and clinical data validates unmet needs.
• AI Applications: Clarified that AI is deployed in three areas: automated patient outreach/return logistics, revenue cycle management (prior auth/claims), and sales territory/account planning.
• New Product Pipeline: Confirmed a late-stage project is nearing FDA submission, expected to be discussed before year-end, and a BP monitoring feature is in the R&D/regulatory cycle.
• Guidelines: Discussed that long-term survival data from the ACE-PASS study will be aggregated over the next 12-18 months to support guideline changes, likely without requiring a new randomized trial.
• Sales Strategy: Confirmed a plan to add 30-40 new sales territories this year, supported by increased medical education efforts and regional training programs.

Other Key Points:

• The company has successfully published post-approval study data involving 21,000 patients, reinforcing the clinical utility of the WCD for non-ischemic cardiomyopathy.
• The "Assure" platform is being positioned not just as a device but as a comprehensive patient care system capable of future expansion into new patient populations.
• Management noted that the therapy conversion rate is 100% for all patients receiving the device, with high adherence (>23 hours/day).
• The business model relies heavily on unit economics and volume leverage to drive gross margin expansion as more patients move into in-network contracts.